Prescription Drugs 2 Go

Updated Date: Sep 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Updated Date: Sep 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Aug 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Aug 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Abstract: The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n=14), Bupropion HCl (n=14), or matching pill placebo (n=15) (random assignment) for 8weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion 11C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was …

Updated Date: Aug 31, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Combination treatment with the anti-addiction drugs naltrexone and Bupropion could help tackle obesity, a study suggests. (Source: HealthcareRepublic Independent Nurse News)

(Source: Reactions)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Despite increasing public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and Bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants. (Source: LANCET)

MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free advertising.

Greenway FL, Fujioka K, Plodkowski RA, et al, for the COR-I Study Group. Effect of naltrexone plus Bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595–605—In figure 3A of this Article (Aug 21), in the graph showing weight loss of 5% or more, an asterisk should have been shown above the bar for naltrexone 32 mg plus Bupropion, in addition to the dagger. This correction has been made to the online version as of Aug 20, 2010, …